medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2007, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2007; 5 (2)

Nail alterations (onicholysis) related to docetaxel administration. Four case reports

Chang P, Samcam NME

Language: Spanish
References: 12
Page: 92-95
PDF size: 280.71 Kb.


ABSTRACT

Four cases of female patients with different types of malignant tumors three with breast cancer and one with advanced gastric carcinoma and lung metastasis– previously treated with docetaxel presenting nail toxicity changes, such as Beau groves, onicholysis and melanonychia, are reported.


REFERENCES

  1. Glivorov J y Jean Pierre Lotz. Preclinical pharmacology of the Taxanes. Implications of the Differences. The Oncologist. 2004; 9 (suppl 2): 3-8

  2. Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Donatella Magri M, Veronessi A, Gatti, A Pérez E. Nail Toxicity Related to Weekly Taxanes: An Important Issue Requiring a Change in Common Toxicity Criteria Grading? J Clin Oncol 2002; 21: 4404-4405

  3. Pérez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2002; 19: 4216-4223

  4. Scotté F, Tourani J.M, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu J, Oudard S. Taxaneinduced nail changes: incidence, clinical presentation and outcome. J Clin Oncol, 2005; 23(19): 4424-4429

  5. Hainsworth JD, Burris HA III, Yardley DA, Bradof JE, Griamldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco A. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001 ; 19: 3500-3505

  6. Piraccini BM, Lorizzo M, Antonucci A, Tosti A. Drug induced nail abnormalities Expert Opin Drug Saf 2004; 3:1 57-65

  7. Tosti A, Baran R, Dawber RPR The nail in systemic diseases and drug induced Changes en: Diseases of the nails and their management. Blackwell Scientific Publication, London, 1994: 239-261

  8. Martindale B. The complete drug reference. 33a. ed. Sweetman et al. Pharmaceutical Press, 2002

  9. British National Formulary (46a. ed.) British Medical Association and Royal Pharmaceutical Society of Great Britain, septiembre de 2003

  10. The Chemotherapy Source Book (3a. ed.) Ed. Perry, Lippincott Williams and Wilkins, 2001

  11. Pronk LC, Stoter G, Verweij J Docetaxel. (Taxotere): single agent activity, development of combination treatment and reaction side effects. Cancer Treatment Reviews 1995; 21: 463-478

  12. Seibel NL, Blaney SM, O’Brien M, Krailo M, Hutchinson R, Mosher RB, Balis FM, Reaman GH. Clinical Cancer Research Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: collaborative pediatric oncology branch. National Cancer Institute and Children’s Cancer Group Trial. Clinical Cancer Research, 1999; 5: 733-737




2020     |     www.medigraphic.com